A. Staab

发表

Good Practices in Model‐Informed Drug Discovery and Development: Practice, Application, and Documentation

S. Marshall, J. Lippert, L. Harnisch, 2016, CPT: pharmacometrics & systems pharmacology.

Semi-mechanistic population pharmacokinetic/pharmacodynamic model for neutropenia following therapy with the Plk-1 inhibitor BI 2536 and its application in clinical development

I. Trocóniz, D. Trommeshauser, A. Staab, 2010, Cancer Chemotherapy and Pharmacology.

Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non‐valvular atrial fibrillation from the RE‐LY trial

S. Yusuf, M. Ezekowitz, S. Connolly, 2011, Journal of thrombosis and haemostasis : JTH.

Population Pharmacokinetic Data Analysis of Cilobradine, an If Channel Blocker

C. Kloft, D. Trommeshauser, A. Staab, 2008, Pharmaceutical Research.

Integration of absorption, distribution, metabolism, and elimination genotyping data into a population pharmacokinetic analysis of nevirapine

Jing Yuan, Hans Guenter Schaefer, Thorsten Lehr, 2011, Pharmacogenetics and genomics.

Biosimulation in Clinical Drug Development

Thorsten Lehr, Alexander Staab, T. Lehr, 2008 .

Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non‐valvular atrial fibrillation from the RE‐LY trial: reply to a rebuttal

S. Yusuf, M. Ezekowitz, S. Connolly, 2012 .

Population pharmacokinetic/pharmacodynamic analysis of the DPP-4 inhibitor linagliptin in Japanese patients with type 2 diabetes mellitus.

M. Takano, A. Sarashina, A. Staab, 2013, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

Population Dose-Response Model for Tadalafil in the Treatment of Male Erectile Dysfunction

I. Trocóniz, A. Staab, C. Tillmann, 2004, Pharmaceutical Research.

A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis.

L. Lands, M. Konstan, S. Heltshe, 2014, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Use of achiral/chiral SFC/MS for the profiling of isomeric cinnamonitrile/hydrocinnamonitrile products in chiral drug synthesis.

A. Alexander, A. Staab, 2006, Analytical chemistry.

Prediction of Neutropenia‐Related Effects of a New Combination Therapy With the Anticancer Drugs BI 2536 (a Plk1 Inhibitor) and Pemetrexed

I. Trocóniz, A. Staab, E. Soto, 2010, Clinical pharmacology and therapeutics.

Modeling and Simulation in Clinical Pharmacology and Dose Finding

L. Aarons, A. Staab, M. Maliepaard, 2013, CPT: Pharmacometrics & Systems Pharmacology.

Tadalafil population pharmacokinetics in patients with erectile dysfunction

I. Trocóniz, A. Staab, C. Tillmann, 2007, European Journal of Clinical Pharmacology.

Comparison of different semi-mechanistic models for chemotherapy-related neutropenia: application to BI 2536 a Plk-1 inhibitor

I. Trocóniz, A. Staab, E. Soto, 2011, Cancer Chemotherapy and Pharmacology.

Quantitative Pharmacology Approach in Alzheimer’s Disease: Efficacy Modeling of Early Clinical Data to Predict Clinical Outcome of Tesofensine

T. Lehr, C. Kloft, D. Trommeshauser, 2010, The AAPS Journal.

Impact of Target‐Mediated Drug Disposition on Linagliptin Pharmacokinetics and DPP‐4 Inhibition in Type 2 Diabetic Patients

U. Jaehde, A. Staab, S. Retlich, 2010, Journal of clinical pharmacology.

Model‐Informed Drug Discovery and Development: Current Industry Good Practice and Regulatory Expectations and Future Perspectives

S. Visser, E. Manolis, A. Staab, 2019, CPT: pharmacometrics & systems pharmacology.

A combined pharmacometric analysis of dabigatran etexilate in healthy volunteers and patients with atrial fibrillation or undergoing orthopaedic surgery

T. Lehr, A. Staab, S. Haertter, 2012, Thrombosis and Haemostasis.

Binding to dipeptidyl peptidase‐4 determines the disposition of linagliptin (BI 1356) – investigations in DPP‐4 deficient and wildtype rats

U. Jaehde, A. Staab, S. Retlich, 2009, Biopharmaceutics & drug disposition.

Pharmacometric Characterization of Dabigatran Hemodialysis

T. Lehr, A. Clemens, A. Staab, 2013, Clinical Pharmacokinetics.

Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumors

A. Staab, U. Schmid, M. Freiwald, 2014, Cancer Chemotherapy and Pharmacology.

Pharmacokinetics and Pharmacodynamics of Single Rising Intravenous Doses (0.5mg–10mg) and Determination of Absolute Bioavailability of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin (BI 1356) in Healthy Male Subjects

U. Jaehde, K. Dugi, S. Hüttner, 2010, Clinical pharmacokinetics.

Wolber Discovery of novel α-amylase inhibitors using structure-based drug design P 2

W. Huisinga, G., U. Holzgrabe, 2014 .

Population Pharmacokinetics and Pharmacodynamics of Linagliptin in Patients with Type 2 Diabetes Mellitus

U. Jaehde, A. Staab, C. Friedrich, 2015, Clinical Pharmacokinetics.

Joint Population Pharmacokinetic/Pharmacodynamic Model for the Heart Rate Effects at Rest and at the End of Exercise for Cilobradine

N. Vélez de Mendizábal, I. Trocóniz, D. Trommeshauser, 2013, Pharmaceutical Research.

Population Pharmacokinetic/Pharmacodynamic Model for the Sedative Effects of Flibanserin in Healthy Volunteers

I. Trocóniz, A. Staab, K. Boland, 2012, Pharmaceutical Research.

A Quantitative Enterohepatic Circulation Model

T. Lehr, C. Kloft, D. Trommeshauser, 2009, Clinical pharmacokinetics.

Semi-Mechanistic Population Pharmacokinetic Drug-Drug Interaction Modelling of a Long Half-Life Substrate and Itraconazole

Hans Guenter Schaefer, Thorsten Lehr, Alexander Staab, 2010, Clinical pharmacokinetics.

Population Pharmacokinetic/Pharmacodynamic Model for the Sedative Effects of Flibanserin in Healthy Volunteers

I. Trocóniz, A. Staab, K. Boland, 2012, Pharmaceutical Research.

A Phase I Dose Escalation Study with Anti-CD44v6 Bivatuzumab Mertansine in Patients with Incurable Squamous Cell Carcinoma of the Head and Neck or Esophagus

Alexander Staab, Remco de Bree, G. Giaccone, 2006, Clinical Cancer Research.

Dabigatran Etexilate in Atrial Fibrillation Patients With Severe Renal Impairment: Dose Identification Using Pharmacokinetic Modeling and Simulation

T. Lehr, A. Clemens, A. Staab, 2012, Journal of clinical pharmacology.

Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck.

C. Kloft, H. Riechelmann, A. Staab, 2007, International journal of oncology.

Clinical trial of a leucotriene B4 receptor antagonist, BIIL 284, in patients with rheumatoid arthritis

Jacques P. Brown, M. Dougados, J. Sibley, 2006, Annals of the rheumatic diseases.

Exposure-response modelling for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes.

T. Macgregor, H. Woerle, M. Gastonguay, 2014, British journal of clinical pharmacology.

Population pharmacokinetics of tamsulosin hydrochloride in paediatric patients with neuropathic and non-neuropathic bladder.

S. Higuchi, A. Sarashina, I. Ieiri, 2010, British journal of clinical pharmacology.

Pharmacokinetics and bioavailability of denaverine hydrochloride in healthy subjects following intravenous, oral and rectal single doses.

A. Staab, B. Schug, E. Mutschler, 2003, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Pharmacometric Models for Characterizing the Pharmacokinetics of Orally Inhaled Drugs

C. Kloft, A. Staab, Benjamin Weber, 2015, The AAPS Journal.

A novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications: an example using DPP-4 inhibitors, sitagliptin and linagliptin, in treatment of type 2 diabetes mellitus

B. Monz, J. Gross, A. Staab, 2013, BMJ Open.

Integration of high-throughput genotyping data into pharmacometric analyses using nonlinear mixed effects modeling

Thorsten Lehr, Hans-Guenter Schaefer, Alexander Staab, 2010, Pharmacogenetics and genomics.

Open Systems Pharmacology Community—An Open Access, Open Source, Open Science Approach to Modeling and Simulation in Pharmaceutical Sciences

Stephan Schmidt, Erik Sjögren, Juri Solodenko, 2019, CPT: pharmacometrics & systems pharmacology.

Modeling Exposure‐Driven Adverse Event Time Courses in Oncology Exemplified by Afatinib

M. Karlsson, A. Staab, H. Maas, 2019, CPT: pharmacometrics & systems pharmacology.

Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study

A. Schneeweiss, F. Schuetz, C. Sohn, 2007, Anti-cancer drugs.

Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacokinetic‐pharmacodynamic modelling approach

T. Lehr, E. Nielsen, C. Kloft, 2008, British journal of pharmacology.

A Semi‐Physiological Model of Amyloid‐β Biosynthesis and Clearance in Human Cerebrospinal Fluid: A Tool for Alzheimer's Disease Research and Drug Development

Thorsten Lehr, Alexander Staab, T. Lehr, 2013, Journal of clinical pharmacology.

Technical Appendix to : A novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications : an example using DPP-4 inhibitors , sitagliptin and linagliptin , in treatment of type 2 diabetes mellitus December

B. Monz, J. Gross, A. Staab, 2012 .

Population pharmacokinetic modelling and simulation of single and multiple dose administration of meloxicam in cats.

T. Lehr, C. Kloft, A. Staab, 2009, Journal of veterinary pharmacology and therapeutics.

Model-based evaluation of pulmonary pharmacokinetics in asthmatic and COPD patients after oral olodaterol inhalation.

Alexander Staab, Charlotte Kloft, Christina Kunz, 2016, British journal of clinical pharmacology.

Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetes

Marc R Gastonguay, Alexander Staab, Sreeraj Macha, 2013, Journal of clinical pharmacology.

Population In Vitro-In Vivo Correlation Model for Pramipexole Slow-Release Oral Formulations

I. Trocóniz, A. Staab, E. Soto, 2010, Pharmaceutical Research.

Investigating pulmonary and systemic pharmacokinetics of inhaled olodaterol in healthy volunteers using a population pharmacokinetic approach.

Alexander Staab, Charlotte Kloft, Christina Kunz, 2016, British journal of clinical pharmacology.

Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer's disease.

T. Lehr, C. Kloft, D. Trommeshauser, 2007, British journal of clinical pharmacology.

Model‐Informed Drug Discovery and Development: Current Industry Good Practice and Regulatory Expectations and Future Perspectives

S. Visser, E. Manolis, A. Staab, 2019, CPT: Pharmacometrics & Systems Pharmacology.